» Studies » Chronic Gout
Learn More About the Location
Oklahoma City-East Side, OKThe purpose of this study is to Evaluate the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate in Participants with Uncontrolled Refractory Gout, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II).
Gout is a form of arthritis that develops when uric acid crystals build up in the body. Uric acid is a waste product. When too much of it is in the bloodstream, it forms crystals over time. People with gout experience pain, redness, swelling, and warmth in the affected joints.
Lynn Institute is a leader in introducing new medications to the market through our clinical trials program. Visit our Participation Information page for Frequently Asked Questions, to see current clinical trials listed, and to find out where each trial is being conducted.
Find out More About Our Participation Program
Participation Information
© 2024 All Rights Reserved by Lynn Institute | Terms & Conditions | Privacy Policy | Website by Digital Space Marketing
